- Previous Close
52.50 - Open
52.80 - Bid 53.10 x --
- Ask 50.10 x --
- Day's Range
51.20 - 52.80 - 52 Week Range
44.85 - 63.50 - Volume
2,656 - Avg. Volume
4,779 - Market Cap (intraday)
497.69M - Beta (5Y Monthly) 0.34
- PE Ratio (TTM)
30.65 - EPS (TTM)
1.69 - Earnings Date --
- Forward Dividend & Yield 0.85 (1.50%)
- Ex-Dividend Date May 6, 2024
- 1y Target Est
84.33
Pharmanutra S.p.A., a pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, Europe, the Middle East, South America, Far East, and internationally. It also produces and markets pharmaceuticals, medical devices, OTC products, and nutraceuticals for pediatric sector; and produces and distributes raw materials and active ingredients for the food, pharmaceutical, and food supplement industries. The company's products primarily include SiderAL, SiderAL Forte, SiderAL Folic, Cardio SiderAL, SiderAL Med, Cetilar Crema, Cetilar Patch, Cetilar Tape, Cetilar Oro, Cetilar Nutrition, ApportAL, UltraMag, Gestalys DHA, Novomega, Bonecal, and DiKappa 2. It distributes and sells its products through sales representatives, wholesalers, pharmacies, and para-pharmacies. The company was founded in 2003 and is based in Pisa, Italy.
www.pharmanutra.it112
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: PHN.MI
View MorePerformance Overview: PHN.MI
Trailing total returns as of 2/7/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PHN.MI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PHN.MI
View MoreValuation Measures
Market Cap
504.42M
Enterprise Value
504.50M
Trailing P/E
31.07
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.45
Price/Book (mrq)
8.56
Enterprise Value/Revenue
4.43
Enterprise Value/EBITDA
16.22
Financial Highlights
Profitability and Income Statement
Profit Margin
13.47%
Return on Assets (ttm)
14.04%
Return on Equity (ttm)
28.01%
Revenue (ttm)
107.61M
Net Income Avi to Common (ttm)
14.5M
Diluted EPS (ttm)
1.69
Balance Sheet and Cash Flow
Total Cash (mrq)
21.81M
Total Debt/Equity (mrq)
49.36%
Levered Free Cash Flow (ttm)
14.48M